To study the clinical effect of mycophenolate mofetil(MMF) on lupus nephritis (LN) and kidney pathology.

From January 2008 to December 2017, 40 patients with lupus nephritis were randomly divided into 2 groups, 20 cases in the control group and 20 cases in the observation group. The control group was treated with cyclophosphamide and the observation group was treated with mycophenolate mofetil based on the control group. The clinical efficacy and adverse reactions of 2 groups were collected after treatment. The disease activity index, renal function index and renal pathological index were compared before and after treatment.

There was no significant difference in the total effective rate between 2 groups(P>0.05). The total effective rate of the observation group was higher than that of the control group(P<0.05). Before treatment, there was no statistical difference in disease activity index, serum creatinine (Scr), blood urea nitrogen (BUN), 24 h urine protein, fibrin crescent, platinum ear and microthrombus(P>0.05). After treatment, compared with the control group, the disease activity index, BUN, Scr, 24 h urine protein and total adverse reaction rate of the observation group had decreased significantly(P<0.05). The fiber cre- scent, white gold ear and microthrombus had significantly decreased in 2 groups after treatment, but the difference between 2 groups had no statistically differences(P>0.05).

Mycophenolate mofetil can achieve the same clinical effect as cyclophosphamide in the treatment of lupus nephritis. Compared with cyclophosphamide, mycophenolate mofetil can reduce the adverse reaction of patients, and its safety is more reliable.

Lupus Nephritis; Mycophenolic Acid